Instadose Pharma Corp. (INSD)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 3604.87 | - |
| Cost of Revenue | - | - | - | - | 1833.64 | - |
| Gross Profit | - | - | - | - | 1771.23 | - |
| Operating Expenses | - | 588.71 Thousand | 33.31 Thousand | 30.92 Thousand | 33.02 Thousand | 41.11 Thousand |
| Selling, General and Administrative Expenses | - | 588.71 Thousand | 33.31 Thousand | 30.92 Thousand | 33.02 Thousand | 41.11 Thousand |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | - | 588.71 Thousand | 33.31 Thousand | 30.92 Thousand | 34.86 Thousand | 41.11 Thousand |
| Operating Income | - | -588.71 Thousand | -33.31 Thousand | -23.27 Thousand | -23.54 Thousand | -31.94 Thousand |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | -364.59 | -16.79 | 7654.26 | -179.57 Thousand | -170.3 Thousand |
| Earnings before Tax | - | -588.71 Thousand | -33.31 Thousand | -30.92 Thousand | -31.25 Thousand | -41.11 Thousand |
| Net Income | - | -588.71 Thousand | -33.31 Thousand | -38.58 Thousand | -31.25 Thousand | -41.11 Thousand |
| Earnings Per Share Basic | - | -0.01 | -0.00 | -0.00 | -0.00 | -0.00 |
| Earnings Per Share Diluted | - | -0.01 | -0.00 | -0.00 | -0.00 | -0.00 |
| Weighted Average Shares Outstanding | - | 75 Million | 75 Million | 75 Million | 75 Million | 75 Million |
| Weighted Average Shares Outstanding (Diluted) | - | 75 Million | 75 Million | 75 Million | 75 Million | 75 Million |
| Gross Margin | - | - | - | - | 0.49 | - |
| EBIT Margin | - | - | - | - | -8.67 | - |
| Profit Margin | - | - | - | - | -8.67 | - |
| EBITDA | - | - | - | -23.27 Thousand | -31.25 Thousand | -31.94 Thousand |
| Earnings Before Tax Margin | - | - | - | - | -6.53 | - |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 FY | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - |
| Selling, General and Administrative Expenses | - | - | - | - | - | - |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | - | - | - | - | - | - |
| Operating Income | - | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | - | - | - | - | - |
| Earnings before Tax | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - |
| Earnings Per Share Basic | - | - | - | - | - | - |
| Earnings Per Share Diluted | - | - | - | - | - | - |
| Weighted Average Shares Outstanding | - | - | - | - | - | - |
| Weighted Average Shares Outstanding (Diluted) | - | - | - | - | - | - |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - |
| Earnings Before Tax Margin | - | - | - | - | - | - |
GRM
BUY
LANV
244920
ARN
VANICOM